The gut-liver axis in fatty liver disease: role played by natural products

被引:4
|
作者
Ming, Zhu [1 ,2 ]
Ruishi, Xie [1 ,2 ]
Linyi, Xu [1 ,2 ]
Yonggang, Yang [3 ]
Haoming, Luo [1 ,2 ]
Xintian, Lan [1 ,2 ]
机构
[1] Changchun Univ Chinese Med, Changchun, Peoples R China
[2] Changchun Univ Chinese Med, Sch Pharm, Changchun, Peoples R China
[3] Baicheng Med Coll, Baicheng 137000, Peoples R China
基金
中国国家自然科学基金;
关键词
gut-liver axis; NAFLD; ALD; natural products; plant metabolites; MICROBIOTA; INJURY; MICE; MECHANISMS; DYSBIOSIS; CIRRHOSIS; BARRIER; PAEONOL; ACIDS;
D O I
10.3389/fphar.2024.1365294
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fatty liver disease, a condition characterized by fatty degeneration of the liver, mainly classified as non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD), has become a leading cause of cirrhosis, liver cancer and death. The gut-liver axis is the bidirectional relationship between the gut and its microbiota and its liver. The liver can communicate with the gut through the bile ducts, while the portal vein transports the products of the gut flora to the liver. The intestinal flora and its metabolites directly and indirectly regulate hepatic gene expression, leading to an imbalance in the gut-liver axis and thus contributing to the development of liver disease. Utilizing natural products for the prevention and treatment of various metabolic diseases is a prevalent practice, and it is anticipated to represent the forthcoming trend in the development of drugs for combating NAFLD/ALD. This paper discusses the mechanism of the enterohepatic axis in fatty liver, summarizes the important role of plant metabolites in natural products in fatty liver treatment by regulating the enterohepatic axis, and provides a theoretical basis for the subsequent development of new drugs and clinical research.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Gut-liver axis
    S. Zeuzem
    International Journal of Colorectal Disease, 2000, 15 : 59 - 82
  • [32] Importance of the gut microbiota in the gut-liver axis in normal and liver disease
    Kotlyarov, Stanislav
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (06)
  • [33] The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective
    De Muynck, Kevin
    Vanderborght, Bart
    Van Vlierberghe, Hans
    Devisscher, Lindsey
    CELLS, 2021, 10 (11)
  • [34] Gut-liver axis in health and disease Abstracts
    不详
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2015, 1 (02) : 51 - 96
  • [35] Acanthopanax seeds polysaccharide improve alcoholic fatty liver disease through the gut-liver axis
    Qin, Liwen
    Piao, Hongjie
    Song, Cuiyu
    Tang, Lingyue
    Yang, Xiao
    Wen, Yuping
    Cui, Hushan
    Jin, Qing
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 301
  • [36] Gut-liver axis in inflammatory bowel disease
    Egresi Anna
    Kovacs Agota
    Szilvas Agnes
    Blazovics Anna
    ORVOSI HETILAP, 2017, 158 (26) : 1014 - 1021
  • [37] The gut-liver axis in liver disease: Pathophysiological basis for therapy
    Albillos, Agustin
    de Gottardi, Andrea
    Rescigno, Maria
    JOURNAL OF HEPATOLOGY, 2020, 72 (03) : 558 - 577
  • [38] Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease
    Castelnuovo, Gabriele
    Perez-Diaz-Del-Campo, Nuria
    Guariglia, Marta
    Poggiolini, Irene
    Armandi, Angelo
    Rosso, Chiara
    Caviglia, Gian P.
    Bugianesi, Elisabetta
    MINERVA GASTROENTEROLOGY, 2024, 70 (04): : 446 - 453
  • [39] The liver X receptor: A master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease
    Ducheix, Simon
    Montagner, Alexandra
    Theodorou, Vassilia
    Ferrier, Laurent
    Guillou, Herve
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (01) : 96 - 105
  • [40] The Gut-Liver Axis in Cholestatic Liver Diseases
    Blesl, Andreas
    Stadlbauer, Vanessa
    NUTRIENTS, 2021, 13 (03) : 1 - 32